NEW YORK – Spectrum Pharmaceuticals said Thursday that its drug candidate poziotinib failed to meet the pre-specified primary endpoint in the first cohort of participants in a Phase II clinical trial investigating patients with pret
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.